Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
228,416,724
-
Total 13F shares
-
162,689,328
-
Share change
-
+102,529
-
Total reported value
-
$222,787,071
-
Put/Call ratio
-
16%
-
Price per share
-
$1.37
-
Number of holders
-
169
-
Value change
-
+$240,755
-
Number of buys
-
76
-
Number of sells
-
66
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2025
As of 31 Dec 2025,
Allogene Therapeutics, Inc. - Common Stock (ALLO) was held by
169 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
162,689,328 shares.
The largest 10 holders included
Pfizer Inc, TPG GP A, LLC, BlackRock, Inc., CITADEL ADVISORS LLC, VANGUARD GROUP INC, PRIMECAP MANAGEMENT CO/CA/, Patient Square Capital LP, GEODE CAPITAL MANAGEMENT, LLC, Frazier Life Sciences Management, L.P., and Woodline Partners LP.
This page lists
169
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.